Cohere AI Updates: May 20, 2026

1. Cohere acquires Reliant AI to launch “North for Pharma” sovereign biopharma stack

Cohere. On May 19, Cohere announced its acquisition of Reliant AI, a Montréal- and Berlin-based biopharma AI startup founded in 2019 by ex-Google researchers Karl Moritz Hermann (CEO), Marc Bellemare (CSO), and Richard Schlegel, with 30+ staff and existing customers GSK, Ipsen, and Kyowa Kirin; financial terms were not disclosed. Reliant’s flagship product, Reliant Tabular, automates systematic literature reviews and asset scans for life-science analysts, and its team, proprietary biomedical datasets, and domain-optimized models will fold into a purpose-built “North for Pharma” version of Cohere’s enterprise agentic platform covering research, clinical development, and scientific analytics. CEO Aidan Gomez framed the deal as targeting “one of the most consequential opportunities for AI” with “secure, sovereign, and domain-specific systems,” extending Cohere’s regulated-industry push less than a month after the Aleph Alpha merger announcement and adding a second German-tied operation to its footprint. Source

2. Acquisition deepens Cohere’s sovereign-AI healthcare positioning

Cohere. Coverage from AIwire on May 19 frames Reliant’s integration as significantly expanding Cohere’s footprint in global healthcare and life sciences, where data privacy, security, and regulatory compliance are gating requirements that have favored sovereign deployments over US-hyperscaler endpoints. The Logic reports the deal is Cohere’s second acquisition in under a month following the April Aleph Alpha takeover, and pairs Reliant’s biomedical datasets with Cohere’s North agentic platform to accelerate drug discovery workflows such as literature review, clinical development, and scientific analytics for biopharma customers. The combination gives Cohere a domain-specific go-to-market wedge into pharma and healthcare buyers as it builds toward a reported 2026 IPO on $240M+ ARR. Source